Mainstay Medical starts commercialization of ReActiv8® for the treatment of Chronic Low Back Pain

on 01/02/2017 10:53

Mainstay confirms its continued eligibility to the PEA-PME

on 30/01/2017 16:58

Mainstay Medical Applies for Approval to Market ReActiv8® in Australia

on 12/01/2017 16:53
Application for inclusion in Australian Register of Therapeutic Goods a key step towards commercialization of innovative treatment of Chronic Low Back Pain in Australian market
Read more

Mainstay Medical announces Half Year Financial Results

on 22/09/2016 10:33

ReActiv8-A Clinical Trial – Sustained Performance at One Year

on 20/09/2016 10:37
One-year data confirm clinically important, statistically significant, and lasting improvement in pain, disability and quality of life for people with Chronic Low Back Pain and limited treatment options
Read more